Developments in the pharmaceutical industry: Is Europe currently losing touch?
Vienna (OTS) – At the imh specialist conference pharmaKON future on May 13, 2024 in Mauerbach Castle Park, what moves the pharmaceutical industry was discussed. Industry as well as ministries and health associations discussed the current status quo regarding financing, health care reform (keyword: evaluation board) and legal changes. With many expectations, we are looking ahead to the government election in the fall.
Active ingredient production made in the EU – a discontinued model?
Dr. Dr. provided information on the topic of medication supply. Wolfgang Andiel from the Generics Association: Europe has lost its strong position as a manufacturer of active ingredients – from 2000 to 2020 the relationship between Europe and Asia has reversed. At the turn of the millennium, 2/3 of the active ingredients were manufactured in Europe, but this quota is now only 1/3. At the same time, he emphasized that even purely European production is not safe from supply bottlenecks. A good solution, however, would be to diversify the supply chain.
Innovation costs money, stable budgets are a must – the pharmaceutical industry is looking forward to the autumn elections
The experts Dr. Alexander Biach (location lawyer from Vienna) and Dr. Stefan Riegler (Federal Ministry of Labor and Economic Affairs) showed the current picture of Austria as a pharmaceutical location: The potential is great, as Austria, and especially Vienna, is at the forefront when it comes to patent applications. In order for this development to continue, stable financing structures are needed in the long term. The hope is that the upcoming government election will treat this issue with the necessary seriousness.
Investment incentives & funding landscape
But a research project alone does not provide any benefit for the patient. The level of knowledge gained through scientific work is high, but implementation is comparatively weak. That’s why a translation to industrial scales is essential. Dr. Biach gave good testimony for the Austrian start-up scene. The quality of support in the form of start-up centers must be right here. But for effective and long-term implementation, stronger cooperation with companies is needed.
About the pharmaKON future
The annual specialist conference pharmaKON future is an important meeting point for the Austrian pharmaceutical industry and healthcare industry.
Since 2022, the experts have been meeting at pharmaKON future in the spring to discuss innovative forms of therapy. This year the conference “Pharmalogistics & Transport” was integrated.
Questions & Contact:
DI Paul Sem, Conference Director
imh Institut Manfred Hämmerle GmbH, Schönbrunner Schlossstraße 4, Top 501, 1120 Vienna
Tel.: +43 1 891 59 702, E-Mail: paul.sem@imh.at, Web: www.imh.at